Signal transduction and oncogenesis by ErbB/HER receptors

Cited by (345)

Items 101–200 of 345

1. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.
   M. Persson, L. Gedda, H. Lundqvist, V. Tolmachev, H. Nordgren, P. Malmström, J. Carlsson · 2007 · Cancer Research
2. Challenges of drug resistance in the management of pancreatic cancer
   Rizwan Masood Sheikh, Naomi Walsh, MARTIN M. CLYNES, Robert A. O'Connor, Ray McDermott · 2010 · Expert Review of Anticancer Therapy
3. Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
   B. Faller, B. Burtness · 2009 · Biologics : Targets & Therapy
4. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin‐based neoadjuvant chemotherapy
   T. Buchholz, X. Tu, K. Ang, F. Esteva, H. Kuerer, L. Pusztai, M. Cristofanilli, S. Singletary, G. Hortobagyi, A. Sahin · 2005 · Cancer
5. Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation.
   Federica Pisaneschi, Q. Nguyen, Elham Shamsaei, M. Glaser, E. Robins, Maciej A. Kaliszczak, Graham Smith, A. Spivey, E. Aboagye · 2010 · Bioorganic & Medicinal Chemistry
6. Targeting growth factors in lung cancer.
   P. Hodkinson, A. Mackinnon, T. Sethi · 2008 · Chest
7. HER2 targeted therapy in breast cancer...beyond Herceptin
   S. Pal, M. Pegram · 2007 · Reviews in Endocrine & Metabolic Disorders
8. Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice
   Wen-Juan Wu, M. O'Reilly, R. Langley, R. Tsan, C. Baker, Neby Bekele, Xi-Ming Tang, A. Onn, I. Fidler, R. Herbst · 2007 · Molecular Cancer Therapeutics
9. Genomics and Cancer Drug Resistance
   António Sebastião Rodrigues, Joana Dinis, Marta Gromicho, Célia Martins, A. Laires, José Rueff · 2012 · Current Pharmaceutical Biotechnology
10. Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Chiara Lazzari, Anna Spreafico, Angela Bachi, Heinrich Röder, Irene Floriani, Daniela Garavaglia, Angela Cattaneo, Julia Grigorieva, Maria Grazia Viganò, Cristina Sorlini et al. · 2011 · Journal of Thoracic Oncology
11. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.
    T. Kuwai, Tõru Nakamura, Takamitsu Sasaki, Sun-jin Kim, D. Fan, G. Villares, M. Zigler, Hua Wang, M. Bar-eli, R. Kerbel et al. · 2008 · Neoplasia
12. In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation
    Harun Patel, Iqrar Ahmad, Rahul H. Pawara, Matin Shaikh, Sanjay Javerilal Surana · 2020 · Journal of Biomolecular Structure and Dynamics
13. Protein Kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer
    Brittany L. Allen-Petersen, C. Carter, A. M. Ohm, M. Reyland · 2013 · Oncogene
14. Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods.
    K. Spindler, J. Lindebjerg, J. Nielsen, D. Olsen, C. Bisgård, I. Brandslund, A. Jakobsen · 2006 · International Journal of Oncology
15. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
    H. Maadi, Babak Nami, Junfeng Tong, Gina Li, Zhixiang Wang · 2018 · BMC Cancer
16. Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
    A. Albini, E. Cesana, F. Donatelli, R. Cammarota, E. Bucci, Massimo Baravelli, C. Anza', D. Noonan · 2011 · Future Cardiology
17. Association of connexin36 and zonula occludens-1 with zonula occludens-2 and the transcription factor zonula occludens-1-associated nucleic acid-binding protein at neuronal gap junctions in rodent retina.
    C. Ciolofan, Xinbo Li, C. O. Olson, N. Kamasawa, B. Gebhardt, T. Yasumura, M. Morita, J. Rash, J. I. Nagy · 2006 · Neuroscience
18. Heat Shock Transcription Factor HSF1 Plays a Critical Role in Cell Migration via Maintaining MAP Kinase Signaling
    Cornelia O'Callaghan-Sunol, M. Sherman · 2006 · Cell Cycle
19. Epidermal growth factor receptor expression in feline oral squamous cell carcinomas.
    J. Looper, D. E. Malarkey, D. Ruslander, David R Proulx, D. Thrall · 2006 · Veterinary and Comparative Oncology
20. Expression of the EGF Family in Gastric Cancer: Downregulation of HER4 and Its Activating Ligand NRG4
    Trine O. Nielsen, L. Friis-Hansen, S. Poulsen, B. Federspiel, B. Sørensen · 2014 · PLoS ONE
21. Transducer of Cdc42-dependent Actin Assembly Promotes Epidermal Growth Factor-induced Cell Motility and Invasiveness*
    Jing-Hui Hu, A. Mukhopadhyay, A. Craig · 2010 · Journal of Biological Chemistry
22. F-BAR-containing adaptor CIP4 localizes to early endosomes and regulates Epidermal Growth Factor Receptor trafficking and downregulation.
    Jing-Hui Hu, Flavia Troglio, A. Mukhopadhyay, Stephanie Everingham, E. Kwok, G. Scita, A. Craig · 2009 · Cellular Signalling
23. Molecular modeling of nearly full-length ErbB2 receptor.
    Péter Bagossi, Gabor L. Horvath, G. Vereb, J. Szöllösi, J. Tőzsér · 2005 · Biophysical Journal
24. MLK3 Signaling in Cancer Invasion
    Chotirat Rattanasinchai, K. Gallo · 2016 · Cancers
25. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
    M. Inoue, F. Koga, S. Yoshida, T. Tamura, Y. Fujii, E. Ito, K. Kihara · 2014 · International Journal of Radiation Oncology, Biology, Physics
26. Lysate Microarrays Enable High-throughput, Quantitative Investigations of Cellular Signaling*
    M. Sevecka, Alejandro Wolf-Yadlin, G. MacBeath · 2011 · Molecular & Cellular Proteomics
27. Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma
    T. Maruyama, K. Mimura, E. Sato, Mitsuaki Watanabe, Yoshiki Mizukami, Yoshihiko Kawaguchi, T. Ando, H. Kinouchi, Hideki Fujii, Koji Kono · 2010 · British Journal of Cancer
28. Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line.
    Lina Ekerljung, Malin Lindborg, L. Gedda, F. Frejd, J. Carlsson, J. Lennartsson · 2008 · Biochemical and Biophysical Research Communications - BBRC
29. ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas.
    A. Yasmeen, T. Bismar, Ala-Eddin Al Moustafa · 2006 · Future Oncology
30. The transition model of RTK activation: a quantitative framework for understanding RTK signaling and RTK modulator activity
    Michael D. Paul, K. Hristova · 2019 · Cytokine & growth factor reviews
31. ErbB2 and NFκB Overexpression as Predictors of Chemoradiation Resistance and Putative Targets to Overcome Resistance in Muscle-Invasive Bladder Cancer
    F. Koga, S. Yoshida, M. Tatokoro, S. Kawakami, Y. Fujii, J. Kumagai, L. Neckers, K. Kihara · 2011 · PLoS ONE
32. Structure-Function Analysis of Nucleolin and ErbB Receptors Interactions
    Keren Farin, A. Di Segni, A. Mor, Ronit Pinkas-Kramarski · 2009 · PLoS ONE
33. Differential sensitivity of A549 non small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors
    María Jaramillo, Myriam Banville, Catherine Collins, Béatrice Paul‐Roc, Lucie Bourget, Maureen D. O'Connor‐McCourt · 2008 · Cancer Biology & Therapy
34. Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line.
    Pavel Bárta, Jennie Malmberg, L. Melicharová, John Strandgård, A. Orlova, V. Tolmachev, M. Lázníček, K. Andersson · 2011 · International Journal of Oncology
35. Flavonoid-enriched extracts from Nelumbo nucifera leaves inhibits proliferation of breast cancer in vitro and in vivo
    Mon‐Yuan Yang, Yun‐Ching Chang, Kuei‐Chuan Chan, Yi‐Ju Lee, Chau‐Jong Wang · 2011 · European Journal of Integrative Medicine
36. Epidermal Growth Factor Receptor-Mediated Membrane Type 1 Matrix Metalloproteinase Endocytosis Regulates the Transition Between Invasive Versus Expansive Growth of Ovarian Carcinoma Cells in Three-Dimensional Collagen
    Natalie M. Moss, Yue-Ying Liu, Jeffrey J. Johnson, P. Debiase, Jonathan C. R. Jones, L. Hudson, H. Munshi, M. Stack · 2009 · Molecular Cancer Research
37. Expression and differential signaling of heregulins in pancreatic cancer cells
    A. Kolb, J. Kleeff, Nichole Boyer Arnold, Nathalia A. Giese, T. Giese, M. Korc, H. Friess · 2007 · International Journal of Cancer
38. Computational Evaluation of Bioactive Compounds from Colocasia affinis Schott as a Novel EGFR Inhibitor for Cancer Treatment
    T. Balogun, N. Ipinloju, O. Abdullateef, Segun I Moses, D. Omoboyowa, A. C. James, Oluwatosin A. Saibu, Wumi F Akinyemi, E. Oni · 2021 · Cancer Informatics
39. Monitoring of receptor dimerization using plasmonic coupling of gold nanoparticles.
    Matthew J. Crow, Kevin Seekell, Julie H. Ostrander, A. Wax · 2011 · ACS Nano
40. Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
    Bonello Maria, Andrew H. Sims, Peter Langdon Simon · 2018 · Cancer Biology and Medicine
41. Profilings of MicroRNAs in the Liver of Common Carp (Cyprinus carpio) Infected with Flavobacterium columnare
    Lijuan Zhao, Hong Lu, Qinglei Meng, Jinfu Wang, Weimin Wang, Ling Yang, Li Lin · 2016 · International Journal of Molecular Sciences
42. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma
    S. Négrier, E. Raymond · 2012 · Investigational new drugs
43. Hyperspectral molecular imaging of multiple receptors using immunolabeled plasmonic nanoparticles.
    Kevin Seekell, Matthew J. Crow, Stella M. Marinakos, Julie H. Ostrander, A. Chilkoti, A. Wax · 2011 · Journal of Biomedical Optics
44. Molecular biology of human epidermal receptors, signaling pathways and targeted therapy against cancers: new evidences and old challenges
    Paulo Michel Pinheiro Ferreira, Cláudia Pessoa · 2017 · Brazilian Journal of Pharmaceutical Sciences
45. Targeted pathways in breast cancer: molecular and protein markers guiding therapeutic decisions.
    H. Kourea, V. Zolota, C. Scopa · 2015 · Current Molecular Pharmacology
46. Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification.
    Alessandra Magnifico, Luisa Albano, S. Campaner, M. Campiglio, S. Pilotti, S. Ménard, E. Tagliabue · 2007 · Cancer Research
47. Cetuximab (Erbitux) – an emerging targeted therapy for epidermal growth factor receptor‐expressing tumours
    M. Ng, D. Cunningham · 2004 · International journal of clinical practice
48. EGFR/MDM2 signaling promotes NF-κB activation via PPARγ degradation.
    Ying Xu, Jian-Hua Jin, Wen-Bo Zhang, Zhi Zhang, Jia-Ming Gao, Qian Liu, Chenglin Zhou, Qinggang Xu, Hai-Feng Shi, Yong-Zhong Hou et al. · 2016 · Carcinogenesis
49. Survivin and pAkt as potential prognostic markers in squamous cell carcinoma of the head and neck.
    A. Pickhard, Simone Gröber, A. Haug, G. Piontek, M. Wirth, U. Strassen, M. Rudelius, R. Reiter · 2014 · Oral surgery, oral medicine, oral pathology and oral radiology
50. Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions.
    S. Kéri, Imola Seres, O. Kelemen, G. Benedek · 2009 · Neurochemistry International
51. Hepatitis B Virus X Upregulates HuR Protein Level to Stabilize HER2 Expression in Hepatocellular Carcinoma Cells
    Chao-Ming Hung, Wei-Chien Huang, Hsiao-Lin Pan, Pei-Hsuan Chien, Chih-Wen Lin, Lei-Chin Chen, Yu-Fong Chien, Ching-Chia Lin, Kar-Hee Leow, Wen-Shu Chen et al. · 2014 · BioMed Research International
52. Oncogenes as Novel Targets for Cancer Therapy (Part I)
    Zhuo Zhang, M. Li, Elizabeth R. Rayburn, Donald L. Hill, Ruiwen Zhang, Hui Wang · 2005 · American Journal of PharmacoGenomics
53. NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib
    I. H. Kankia, Hilal S. Khalil, S. Langdon, P. Moult, J. Bown, Y. Deeni · 2017 · Oxidative Medicine and Cellular Longevity
54. Quantification of PKC family genes in sporadic breast cancer by qRT‐PCR: Evidence that PKCι/λ overexpression is an independent prognostic factor
    K. Awadelkarim, C. Callens, C. Rossé, A. Susini, S. Vacher, E. Rouleau, R. Lidereau, I. Bièche · 2012 · International Journal of Cancer
55. Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells.
    J. Riedemann, Muhammad Sohail, V. Macaulay · 2007 · Biochemical and Biophysical Research Communications - BBRC
56. (−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells
    Jing Wang, Pei-Yuan Sun, Qi Wang, Pan Zhang, Yuna Wang, Cheng-Ting Zi, Xuan-Jun Wang, J. Sheng · 2019 · Cancer Cell International
57. Role of erlotinib in the management of pancreatic cancer
    N. Starling, J. Neoptolemos, D. Cunningham · 2006 · Therapeutics and Clinical Risk Management
58. Mechanism of action of potato carboxypeptidase inhibitor (PCI) as an EGF blocker.
    Marta Sitjà-Arnau, M. Molina, C. Blanco-Aparicio, Laura Ferrer-Soler, J. Lorenzo, F. Avilés, E. Querol, R. de Llorens · 2005 · Cancer Letters
59. Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
    F. Concha-Benavente, R. Ferris · 2017 · Frontiers in Pharmacology
60. Investigation of gene effects and epistatic interactions between Akt1 and neuregulin 1 in the regulation of behavioral phenotypes and social functions in genetic mouse models of schizophrenia
    Ching-Hsun Huang, Ju-Chun Pei, Da-Zhong Luo, Ching-Tsuey Chen, Yi-Wen Chen, W. Lai · 2015 · Frontiers in Behavioral Neuroscience
61. Reorganization of ErbB Family and Cell Survival Signaling after Knock-down of ErbB2 in Colon Cancer Cells*
    Y. Hu, S. Venkateswarlu, N. Sergina, G. Howell, P. St. Clair, L. Humphrey, Wen-hui Li, J. Hauser, E. Zborowska, J. Willson et al. · 2005 · Journal of Biological Chemistry
62. Orlistat: From Antiobesity Drug to Anticancer Agent in Her-2/neu (erbB-2)-Overexpressing Gastrointestinal Tumors?
    J. Menéndez, L. Vellon, R. Lupu · 2005 · Experimental biology and medicine
63. Inhibition of ErbB2 by Herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line
    Irem Dogan, A. Cumaoğlu, A. Aricioglu, A. Ekmekçi · 2010 · Molecular and Cellular Biochemistry
64. <i>In vitro</i> combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells
    Luca, T., Barresi, V., Privitera, G., Musso, N., Caruso, M., Condorelli, D. F., Castorina, S. · 2014 · Cell Proliferation
65. Hepatic transcriptomic adaptation from prepartum to postpartum in dairy cows.
    S-T Gao, D. D. Girma, M. Bionaz, L. Ma, D. Bu · 2020 · Journal of Dairy Science
66. Generation and Evaluation of Bispecific Affibody Molecules for Simultaneous Targeting of EGFR and HER2
    Lina Ekerljung, Helena Wållberg, Azita Sohrabian, Karl Andersson, Mikaela Friedman, Fredrik Y. Frejd, Stefan Ståhl, Lars Gedda · 2012 · Bioconjugate Chemistry
67. Integrin β1 mediates epithelial growth factor-induced invasion in human ovarian cancer cells.
    Man-Tat Lau, Wai-Kin So, P. Leung · 2012 · Cancer Letters
68. Dual targeting of EGFR and HER-2 in colon cancer cell lines
    E. Giannopoulou, A. Antonacopoulou, Konstantina Floratou, A. Papavassiliou, H. Kalofonos · 2009 · Cancer Chemotherapy and Pharmacology
69. Effects of HER2-Binding Affibody Molecules on Intracellular Signaling Pathways
    Lina Ekerljung, Ann-Charlott Steffen, J. Carlsson, J. Lennartsson · 2006 · Tumor Biology
70. Emerging role of phytochemicals in targeting predictive, prognostic, and diagnostic biomarkers of lung cancer.
    Jyoti Singh, Suaib Luqman, Abha Meena · 2020 · Food and Chemical Toxicology
71. Identification and analysis of dysregulated lncRNA and associated ceRNA in the pathogenesis of keloid
    Xi-Lei Duan, Yuemeng Wu, Zheng Zhang, Zhong Lu · 2020 · Annals of Translational Medicine
72. Epidermal growth factor as a mechanosensitizer in human bone marrow stromal cells.
    S. Müller-Deubert, L. Seefried, Melanie Krug, F. Jakob, R. Ebert · 2017 · Stem Cell Research
73. Fluorogen Activating Protein–Affibody Probes: Modular, No-Wash Measurement of Epidermal Growth Factor Receptors
    Yi Wang, C. Telmer, B. Schmidt, J. Franke, Stephan Ort, D. Arndt-Jovin, M. Bruchez · 2014 · Bioconjugate chemistry
74. Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab.
    Jennie Malmberg, V. Tolmachev, A. Orlova · 2011 · International Journal of Oncology
75. Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex.
    T. B. Deb, An-Nie H. Zuo, You-Hong Wang, Robert J. Barndt, A. Cheema, S. Sengupta, Christine M. Coticchia, M. Johnson · 2011 · American Journal of Physiology - Cell Physiology
76. PPARδ is a regulator of autophagy by its phosphorylation
    Qian Gou, Yidan Jiang, Runyun Zhang, Ying Xu, Huihui Xu, Wenbo Zhang, Juanjuan Shi, Yongzhong Hou · 2020 · Oncogene
77. Epidermal Growth Factor Signaling towards Proliferation: Modeling and Logic Inference Using Forward and Backward Search
    A. Riesco, Beatriz Santos-Buitrago, J De Las Rivas, M. Knapp, Gustavo Santos-García, C. Talcott · 2017 · BioMed Research International
78. Clustered localization of EGFRvIII in glioblastoma cells as detected by high precision localization microscopy.
    Philip S. Boyd, N. Struve, Margund Bach, J. Eberle, M. Gote, F. Schock, C. Cremer, M. Kriegs, M. Hausmann · 2016 · Nanoscale
79. The two sides of HER2/neu: immune escape versus surveillance
    Barbara Seliger, Rolf W. Kiessling · 2013 · Trends in Molecular Medicine
80. Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
    Christina Kline, Wafik S. El‐Deiry · 2013 · Pharmaceuticals
81. Chronic Morphine Treatment Attenuates Cell Growth of Human BT474 Breast Cancer Cells by Rearrangement of the ErbB Signalling Network
    Inka Regine Weingaertner, Sarah Koutnik, Hermann Ammer · 2013 · PLoS ONE
82. Regulation of HRG-β1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression.
    Shu-qin Ruan, Shan-wei Wang, Zhan-huai Wang, Su-Zhan Zhang · 2012 · Molecular Medicine Reports
83. Endogenous Neuregulin Restores Radial Glia in a (Ferret) Model of Cortical Dysplasia
    M. Gierdalski, S. Sardi, G. Corfas, S. Juliano · 2005 · Journal of Neuroscience
84. Ligand‐independent epidermal growth factor receptor hyperactivation increases sebaceous gland size and sebum secretion in mice
    Dahlhoff, Maik, de Angelis, Martin Hrabe, Wolf, Eckhard, Schneider, Marlon R. · 2013 · Experimental Dermatology
85. Cord Blood Stem Cells Inhibit Epidermal Growth Factor Receptor Translocation to Mitochondria in Glioblastoma
    Venkata Ramesh Dasari, Kiran Kumar Velpula, Kiranmai Alapati, Meena Gujrati, Andrew J. Tsung · 2012 · PLoS ONE · Retracted
86. Neuregulin-regulated gene expression in mammary carcinoma cells.
    Dhara N. Amin, D. Tuck, D. Stern · 2005 · Experimental Cell Research
87. Oncogenes as Novel Targets for Cancer Therapy (Part IV)
    Zhuo Zhang, M. Li, Elizabeth R. Rayburn, Donald L. Hill, Ruiwen Zhang, Hui Wang · 2005 · American Journal of PharmacoGenomics
88. Characterization of the diffusion of epidermal growth factor receptor clusters by single particle tracking.
    M. Boggara, Krishna Athmakuri, S. K. Srivastava, Richard Cole, R. Kane · 2013 · Biochimica et Biophysica Acta
89. The “HER2–PI3K/Akt–FASN Axis” Regulated Malignant Phenotype of Colorectal Cancer Cells
    Nan Li, Xiao-Dong Bu, Peng Wu, Ping-Ping Wu, Pei-Lin Huang · 2012 · Lipids
90. HER3 Alterations in Cancer and Potential Clinical Implications
    Kilroy, Mary Kate, Park, SoYoung, Feroz, Wasim, Patel, Hima, Mishra, Rosalin, Alanazi, Samar, Garrett, Joan T. · 2022 · Cancers
91. Opportunities and challenges for the development of covalent chemical immunomodulators
    Keriann M. Backus, Jian Xin Cao, Sean M. Maddox · 2019 · Bioorganic & Medicinal Chemistry
92. Monoclonal Antibodies Approved for Cancer Therapy
    B. Baldo · 2016 · Safety of Biologics Therapy
93. Targeting HER2 Epitopes.
    S. Pal, M. Pegram · 2006 · Seminars in Oncology
94. A narrative review of the role of common EGFR mutations in pathogenesis and treatment of non-small-cell lung carcinoma
    Mansi Sharma, Dharmishtha Ashis Basu, Shrinidhi Nathany, B. P. Amrith, Ullas Batra · 2022 · Cancer Research Statistics and Treatment
95. Oncogenic growth factor signaling mediating tumor escape from cellular immunity
    F. Concha-Benavente, R. Ferris · 2017 · Current Opinion in Immunology
96. Signaling pathways influencing tumor microenvironment and their exploitation for targeted drug delivery
    Caroline J. Sheeba, Gregory Marslin, Ann Mary Revina, Gregory Franklin · 2013 · Nanotechnology Reviews
97. Label-free cell phenotypic assessment of the molecular mechanism of action of epidermal growth factor receptor inhibitors
    Hua-Yun Deng, Chaoming Wang, Ye Fang · 2013
98. Targeting multiple kinases in glioblastoma multiforme
    S. Sathornsumetee, D. Reardon · 2009 · Expert Opinion on Investigational Drugs
99. The emergence of ErbB2 expression in cultured rat hepatocytes correlates with enhanced and diversified EGF-mediated signaling.
    L. A. Scheving, Linda Zhang, M. Stevenson, Eun Soo Kwak, W. E. Russell · 2006 · American Journal of Physiology - Gastrointestinal and Liver Physiology
100. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors
     N. Fazio, C. Cella, M. Del Re, A. Laffi, M. Rubino, P. Zagami, F. Spada · 2019 · Expert Opinion on Drug Metabolism & Toxicology